Personal information

Other IDs

Scopus Author ID: 57516111100

Activities

Collapse all

Works (14)

Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024-09-16 | Preprint
DOI: 10.1158/0008-5472.c.6653403.v3
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar. Pandey; Anshu Kuriakose; Shivakumar Bhadravathi. Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024-09-16 | Preprint
DOI: 10.1158/0008-5472.c.6653403
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar. Pandey; Anshu Kuriakose; Shivakumar Bhadravathi. Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024-09-16 | Preprint
DOI: 10.1158/0008-5472.27027566
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar. Pandey; Anshu Kuriakose; Shivakumar Bhadravathi. Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024-09-16 | Preprint
DOI: 10.1158/0008-5472.27027566.v1
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar. Pandey; Anshu Kuriakose; Shivakumar Bhadravathi. Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

Cancer research
2023 | Journal article
DOI: 10.1158/0008-5472.CAN-21-4425
EID:

2-s2.0-85160970345

Part of ISSN: 15387445
Contributors: Boreddy, S.R.; Nair, R.; Pandey, P.K.; Kuriakose, A.; Marigowda, S.B.; Dey, C.; Banerjee, A.; Kulkarni, H.; Sagar, M.; Krishn, S.R. et al.
Source: Self-asserted source
Milind Sagar via Scopus - Elsevier
grade
Preferred source (of 2)‎

Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-06-02 | Preprint
DOI: 10.1158/0008-5472.c.6653403.v2
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-06-02 | Preprint
DOI: 10.1158/0008-5472.23283315.v1
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-06-02 | Preprint
DOI: 10.1158/0008-5472.23283315
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-05-18 | Preprint
DOI: 10.1158/0008-5472.c.6653403.v1
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-05-18 | Preprint
DOI: 10.1158/0008-5472.22929363
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023-05-18 | Preprint
DOI: 10.1158/0008-5472.22929363.v1
Contributors: Srinivas Reddy Boreddy; Reshmi Nair; Prashant Kumar Pandey; Anshu Kuriakose; Shivakumar Bhadravathi Marigowda; Chaitali Dey; Arindam Banerjee; Hanumant Kulkarni; Milind Sagar; Shiv Ram Krishn et al.
Source: check_circle
Crossref

Significance of animal experimentation in biomedical research in the current era: Narrative review

Journal of Applied Pharmaceutical Science
2022 | Journal article
DOI: 10.7324/JAPS.2022.121002-1
EID:

2-s2.0-85140009634

Part of ISSN: 22313354
Contributors: Sakat, S.S.; Bagade, O.; Mhaske, G.; Taru, P.; Sagar, M.; Rastogi, M.
Source: Self-asserted source
Milind Sagar via Scopus - Elsevier

Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors

Journal of Medicinal Chemistry
2020 | Journal article
DOI: 10.1021/acs.jmedchem.0c01061
EID:

2-s2.0-85092749685

Part of ISSN: 15204804 00222623
Contributors: Mahajan, D.; Sen, S.; Kuila, B.; Sharma, A.; Arora, R.; Sagar, M.; Mahapatra, A.R.; Gawade, L.B.; Dugar, S.
Source: Self-asserted source
Milind Sagar via Scopus - Elsevier

Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition

Molecular Carcinogenesis
2017 | Journal article
DOI: 10.1002/mc.22526
EID:

2-s2.0-84982966414

Part of ISSN: 10982744 08991987
Contributors: Kulsum, S.; Sudheendra, H.V.; Pandian, R.; Ravindra, D.R.; Siddappa, G.; Nisheena, R.; Chevour, P.; Ramachandran, B.; Sagar, M.; Jayaprakash, A. et al.
Source: Self-asserted source
Milind Sagar via Scopus - Elsevier
How many people are using ORCID?